Specialty Drug Approvals: 2015 Highlights + 2016 Projections
In 2015, the recent trend continued with a greater-than-average number of drug approvals compared to past years. Special FDA designations such as breakthrough, fast track, orphan, accelerated approval and priority review have been applied to promising drugs or those that treat diseases with an unmet medical need. These designations have reduced the time needed for clinical trials and/or reduced the FDA review timeline, allowing pipeline products to come to market more quickly than in the past.1
Sign up to read our White Paper and receive helpful updates from Diplomat.
1. Developing products for rare disease & conditions. U.S. Food and Drug Administration (FDA) Website. Accessed December 1, 2015.
@DiplomatRx@BuntyLUFC We appreciate you reaching out. Would you mind direct messaging us so we can help?3 days ago
@DiplomatRxOur Navigating Patient Engagement webinar is available on demand. Sign up at https://t.co/LN1qWkrCZp to watch the r… https://t.co/RaQGhk3xF73 days ago
@SpecialtyPharmRT @SpecialtyPharm: Specialty Pharmacies Earn High Marks in First NASP Patient Satisfaction @Rx_Specialty Survey #NASP2017 https://t.co/B0k…3 days ago
@DiplomatRxDid you miss yesterday's Navigating Patient Engagement webinar? If so, register below to view it on demand.… https://t.co/SHcloxFFXP2 weeks ago
@DiplomatRx"We're going live today with our new pharma webinar! Tune in at 12 p.m. ET at the link below."—Cheryl Allen… https://t.co/6ejXSvYDKA2 weeks ago